Literature DB >> 20179675

Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery.

Minna U Kaikkonen1, Antti I Maatta, Seppo Ylä-Herttuala, Kari J Airenne.   

Abstract

One of the major obstacles in the use of baculovirus vectors for in vivo gene transfer is the virus inactivation by serum complement. In this study, we investigated the effect of decay-accelerating factor (DAF), factor H (FH)-like protein-1 (FHL-1), C4b-binding protein (C4BP), and membrane cofactor protein (MCP) on protection of baculovirus vectors from the complement-mediated inactivation. Complement regulatory proteins were displayed on baculovirus surface as fusions to membrane anchor of the vesicular stomatitis virus-G (VSV-G) protein. This strategy resulted in abundant expression of recombinant proteins on the viral envelope while viral titers comparable to control virus were reached. The surface-modified vectors exhibited complement resistance in vitro, DAF showing the highest level of protection. Intraportal delivery of DAF-displaying baculovirus resulted in increased survival and enhanced gene expression in immunocompetent mice. Mice receiving DAF-displaying baculovirus also exhibited lower level of liver inflammation as evidenced by aspartate aminotransferase (AST). In line with this, macrophages treated with DAF baculovirus produced lower levels of inflammatory cytokines IL-1beta, IL-6, and IL-12p40 compared to control virus. These results suggest that DAF-display can protect the vector against complement inactivation but also reduce complement-mediated inflammation injury. In conclusion, complement shielded baculovirus vectors represent attractive tools for effective in vivo gene delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179675      PMCID: PMC2890102          DOI: 10.1038/mt.2010.25

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  Truncated vesicular stomatitis virus G protein improves baculovirus transduction efficiency in vitro and in vivo.

Authors:  M U Kaikkonen; J K Räty; K J Airenne; T Wirth; T Heikura; S Ylä-Herttuala
Journal:  Gene Ther       Date:  2006-02       Impact factor: 5.250

2.  Modulation of chondrocyte phenotype via baculovirus-mediated growth factor expression.

Authors:  Li-Yu Sung; Wen-Hsin Lo; Hsin-Yi Chiu; Huang-Chi Chen; Ching-Kuang Chung; Hsiao-Ping Lee; Yu-Chen Hu
Journal:  Biomaterials       Date:  2007-04-12       Impact factor: 12.479

3.  Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease.

Authors:  Mehdi Mohamadnejad; Ghodrat Montazeri; Atoosa Fazlollahi; Farhad Zamani; Jafar Nasiri; Hossein Nobakht; Mohammad Hossein Forouzanfar; Shifteh Abedian; Seyed Mohamad Tavangar; Ashraf Mohamadkhani; Farhad Ghoujeghi; Arezoo Estakhri; Negin Nouri; Zahra Farzadi; Abolfazl Najjari; Reza Malekzadeh
Journal:  Am J Gastroenterol       Date:  2006-10-04       Impact factor: 10.864

4.  Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.

Authors:  Ghiabe H Guibinga; Theodore Friedmann
Journal:  Mol Ther       Date:  2005-04       Impact factor: 11.454

Review 5.  Membrane complement regulatory proteins.

Authors:  David D Kim; Wen-Chao Song
Journal:  Clin Immunol       Date:  2005-12-09       Impact factor: 3.969

6.  Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood.

Authors:  Lindsay J Georgopoulos; Graciela Elgue; Javier Sanchez; Vincent Dussupt; Paola Magotti; John D Lambris; Thomas H Tötterman; Norman J Maitland; Bo Nilsson
Journal:  Mol Immunol       Date:  2009-08-08       Impact factor: 4.407

7.  Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy.

Authors:  Chao-Yang Wang; Feng Li; Yi Yang; Hai-Yan Guo; Chun-Xiao Wu; Shu Wang
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo.

Authors:  Xinhua Zhang; Yuko Kimura; Chongyun Fang; Lin Zhou; Georgia Sfyroera; John D Lambris; Rick A Wetsel; Takashi Miwa; Wen-Chao Song
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

9.  Baculovirus as a new gene delivery vector for stem cell engineering and bone tissue engineering.

Authors:  C-K Chuang; L-Y Sung; S-M Hwang; W-H Lo; H-C Chen; Y-C Hu
Journal:  Gene Ther       Date:  2007-07-19       Impact factor: 5.250

10.  Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.

Authors:  Masayuki Kitajima; Takayuki Abe; Naoko Miyano-Kurosaki; Masaru Taniguchi; Toshinori Nakayama; Hiroshi Takaku
Journal:  Mol Ther       Date:  2007-12-04       Impact factor: 11.454

View more
  13 in total

1.  Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells.

Authors:  Tomoyuki Suzuki; Myint Oo Chang; Masayuki Kitajima; Hiroshi Takaku
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

Review 2.  Baculovirus: an insect-derived vector for diverse gene transfer applications.

Authors:  Kari J Airenne; Yu-Chen Hu; Thomas A Kost; Richard H Smith; Robert M Kotin; Chikako Ono; Yoshiharu Matsuura; Shu Wang; Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

3.  Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo.

Authors:  Wen-Yi Luo; Shih-Yeh Lin; Kai-Wei Lo; Chia-Hsin Lu; Chang-Lin Hung; Chi-Yuan Chen; Chien-Chung Chang; Yu-Chen Hu
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

Review 4.  Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials.

Authors:  Timothy Weixin Kwang; Xinhui Zeng; Shu Wang
Journal:  Mol Ther Methods Clin Dev       Date:  2016-01-27       Impact factor: 6.698

Review 5.  Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications.

Authors:  Chi-Yuan Chen; Chin-Yu Lin; Guan-Yu Chen; Yu-Chen Hu
Journal:  Biotechnol Adv       Date:  2011-04-28       Impact factor: 14.227

Review 6.  Non-human viruses developed as therapeutic agent for use in humans.

Authors:  Danijela Koppers-Lalic; Rob C Hoeben
Journal:  Rev Med Virol       Date:  2011-05-11       Impact factor: 6.989

7.  Evaluating baculovirus as a vector for human prostate cancer gene therapy.

Authors:  Stephanie L Swift; Guillermo C Rivera; Vincent Dussupt; Regina M Leadley; Lucy C Hudson; Corrina Ma de Ridder; Robert Kraaij; Julie E Burns; Norman J Maitland; Lindsay J Georgopoulos
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

Review 8.  Baculovirus-mediated gene delivery and RNAi applications.

Authors:  Kaisa-Emilia Makkonen; Kari Airenne; Seppo Ylä-Herttulala
Journal:  Viruses       Date:  2015-04-22       Impact factor: 5.048

9.  Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization.

Authors:  Arghya Paul; Cynthia B Elias; Dominique Shum-Tim; Satya Prakash
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice.

Authors:  Mitsuhiro Iyori; Daisuke S Yamamoto; Miako Sakaguchi; Masanori Mizutani; Sota Ogata; Hidesato Nishiura; Takahiko Tamura; Hiroyuki Matsuoka; Shigeto Yoshida
Journal:  Malar J       Date:  2017-09-29       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.